Aetiology, practice patterns and burden of end-stage kidney disease in South Asia and South-East Asia: A questionnaire-based survey

Manisha Sahay, Sanjiv Jasuja*, Sydney Chi Wai Tang, Suceena Alexander, Vivekanand Jha, Tushar Vachharajani, Mamun Mostafi, Jayakrishnan K. Pisharam, Chakko Jacob, Atma Gunawan, Goh Bak Leong, Khin Thida Thwin, Rajendra Kumar Agrawal, Kriengsak Vareesangthip, Roberto Tanchanco, Lina Choong, Chula Herath, Chih Ching Lin, Nguyen The Cuong, Ha Phan HaianSyed Fazal Akhtar, Ali Alsahow, Devinder S. Rana, Mohan M. Rajapurkar, Vijay Kher, Shalini Verma, Raja Ramachandran, Vinant Bhargava, Sonika Puri, Gaurav Sagar, Anupam Bahl, Sandeep Mandal, Ashwani Gupta, Maurizio Gallieni

*此作品的通信作者

研究成果: Article同行評審

3 引文 斯高帕斯(Scopus)

摘要

Aim: There is paucity of data on the epidemiology of end-stage kidney disease (ESKD) from South Asia and South-East Asia. The objective of this study was to assess the aetiology, practice patterns and disease burden and growth of ESKD in the region comparing the economies. Methods: The national nephrology societies of the region; responded to the questionnaire; based on latest registries, acceptable community-based studies and society perceptions. The countries in the region were classified into Group 1 (High|higher-middle-income) and Group 2 (lower|lowermiddle income). Student t-test, Mann-Whitney U test and Fisher's exact test were used for comparison. Results: Fifteen countries provided the data. The average incidence of ESKD was estimated at 226.7 per million population (pmp), (Group 1 vs. Group 2, 305.8 vs. 167.8 pmp) and average prevalence at 940.8 pmp (Group 1 vs. Group 2, 1306 vs. 321 pmp). Group 1 countries had a higher incidence and prevalence of ESKD. Diabetes, hypertension and chronic glomerulonephritis were most common causes. The mean age in Group 2 was lower by a decade (Group 1 vs. Group 2—59.45 vs 47.7 years). Conclusion: Haemodialysis was the most common kidney replacement therapy in both groups and conservative management of ESKD was the second commonest available treatment option within Group 2. The disease burden was expected to grow >20% in 50% of Group 1 countries and 78% of Group 2 countries along with the parallel growth in haemodialysis and peritoneal dialysis.

原文English
頁(從 - 到)142-152
頁數11
期刊Nephrology
26
發行號2
DOIs
出版狀態Published - 2月 2021

指紋

深入研究「Aetiology, practice patterns and burden of end-stage kidney disease in South Asia and South-East Asia: A questionnaire-based survey」主題。共同形成了獨特的指紋。

引用此